Literature DB >> 33505608

The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature.

Evangelos Karvounis1, Ioannis Kappas1, Anna Angelousi2, George-Marios Makris3, Thomas D Siamatras1, Eva Kassi2,4.   

Abstract

The purpose of the present study is to examine the diagnostic and predictive accuracy of the thyroglobulin (Tg) to thyroid stimulating hormone (TSH) and TSH/Tg ratios in normothyroid patients with differentiated thyroid cancer (DTC). We conducted a retrospective cohort study evaluating the diagnostic accuracy of the serum Tg/TSH and TSH/Tg ratios in normothyroid patients with thyroid nodules. We also systematically searched the international literature using the Medline, Cochrane's CENTRAL, Scopus, Clinicaltrials.gov, EMBASE, and Google Scholar databases for evidence concerning the diagnostic and predictive accuracy of these ratios. Overall, 374 patients were identified in our cohort study of whom 240 were treated for benign disease and 134 were treated for DTC. Significant differences were noted in the Tg/TSH and TSH/Tg values among cases with malignant and benign disease (P=0.020). However, the diagnostic ROC curve did not confirm these results (Tg/TSH=0.572 and TSH/Tg=0.428). After searching the international literature, we identified 8 studies. The majority of the included data reported significant differences among patients with benign/malignant disease and those with successful iodine therapy compared to those with disease relapse. However, the clinical relevance was clearer among studies that investigated the usefulness of these ratios in predicting recurrent disease. The findings of our study support that the Tg/TSH ratio increases in patients with DTC and can, thus, become useful in the future as a predictive marker of ablative 131I therapy success. However, given the significant variability of Tg its diagnostic accuracy remains to date minimal; thus, the actual cut-off value that can be used to discriminate cancer cases from benign disease has not been determined yet. ©Copyright: the Author(s).

Entities:  

Keywords:  TSH; Tg; iodine therapy; systematic review; thyroglobulin; thyroid cancer

Year:  2021        PMID: 33505608      PMCID: PMC7814274          DOI: 10.4081/oncol.2020.439

Source DB:  PubMed          Journal:  Oncol Rev        ISSN: 1970-5557


  23 in total

1.  Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.

Authors:  H Shimura; H Suzuki; A Miyazaki; F Furuya; K Ohta; K Haraguchi; T Endo; T Onaya
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

3.  Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.

Authors:  Yul Hwangbo; Jung Min Kim; Young Joo Park; Eun Kyung Lee; You Jin Lee; Do Joon Park; Young Sik Choi; Kang Dae Lee; Seo Young Sohn; Sun Wook Kim; Jae Hoon Chung; Dong Jun Lim; Min Hee Kim; Min Joo Kim; Young Suk Jo; Min Ho Shong; Sung-Soo Koong; Jong Ryeal Hahm; Jung Hwa Jung; Ka Hee Yi
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

Review 4.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

5.  Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers.

Authors:  Paula Grasiele Carvalho Trevizam; José Vicente Tagliarini; Emanuel Celice Castilho; Mariângela de Alencar Marques; Yoshio Kiy; Gláucia Maria Ferreira da Silva Mazeto
Journal:  Endocr Res       Date:  2016-05-04       Impact factor: 1.720

6.  Thyroid Peroxidase and Thyroglobulin Expression in Normal Human Thyroid Glands.

Authors:  Marcus A. Lima; Vakria A. Gontijo; Fernando C. L. Schmitt
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

7.  Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.

Authors:  Young Woo Chang; Hwan Soo Kim; Seung Pil Jung; Hoon Yub Kim; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son
Journal:  Int J Clin Oncol       Date:  2016-02-02       Impact factor: 3.402

8.  Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.

Authors:  Jen-Der Lin; Chuen Hsueh; Tzu-Chieh Chao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.

Authors:  Syed Zubair Hussain; Maseeh Uz Zaman; Sarwar Malik; Nanik Ram; Ali Asghar; Unaib Rabbani; Nida Aftab; Najmul Islam
Journal:  J Thyroid Res       Date:  2014-04-09

10.  Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.

Authors:  Seul Gi Lee; Joon Ho; Jung Bum Choi; Tae Hyung Kim; Min Jhi Kim; Eun Jeong Ban; Cho Rok Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Sang Geun Jung; Young Suk Jo; Jandee Lee; Woong Youn Chung
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.